Oyster Point Pharma Announces FDA Clearance of Investigational New Drug Application for the Treatment of Dry Eye Disease

by Business Wire • 2018/06/27 • 0 Comments

PRINCETON, N.J.--(BUSINESS WIRE)--#DryEye--Oyster Point Pharma Announces FDA Clearance of Investigational New Drug Application for the Treatment of Dry Eye Disease.

← Innovations in Eye Disease Diagnosis, Thermal Imaging, Breast Cancer Diagnosis, Malaria Diagnosis, Stroke Detection, and MRI, 2018 Report – ResearchAndMarkets.com

HeartFlow Announces New Commercial Coverage With UnitedHealthcare, Largest Health Insurer in U.S. →

Post navigation